Urticaria | Unmet Need | Chronic Inducible and Chronic Spontaneous | US/EU | 2021

The urticaria drug market is dominated by oral medications, including second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair (Novartis / Genentech) has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.


  • What unmet needs remain for chronic urticaria patients after the approval of Xolair?
  • Which clinical trial endpoints and nonclinical attributes are key influencers on dermatologists’ and allergists’ prescribing decisions and which have limited impact? What are potential areas of hidden opportunity?
  • How does Xolair perform on key treatment drivers and goals? How does its performance compare with that of frequently prescribed conventional therapies, including immunosuppressants and antihistamines?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists and allergists for a hypothetical new chronic urticaria drug?


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European allergists and dermatologists fielded in April 2021

Key companies: Novartis, AbbVie

Key drugs: Xolair, Humira, antihistamines, immunosuppressants

Login to access report